Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?
Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality? A meta-analysis of observational studies Ajay D. Rao , MD 1 , Nitesh Kuhadiya , MBBS 2 , Kristi Reynolds , PHD, MPH 2 , 3 and Vivian A. Fonseca , MD 1 1 Department of...
Uložené v:
| Vydané v: | Diabetes care Ročník 31; číslo 8; s. 1672 - 1678 |
|---|---|
| Hlavní autori: | , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Alexandria
American Diabetes Association
01.08.2008
|
| Predmet: | |
| ISSN: | 0149-5992, 1935-5548 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Shrnutí: | Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause
Mortality?
A meta-analysis of observational studies
Ajay D. Rao , MD 1 ,
Nitesh Kuhadiya , MBBS 2 ,
Kristi Reynolds , PHD, MPH 2 , 3 and
Vivian A. Fonseca , MD 1
1 Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana
2 Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana
3 Southern California Kaiser Permanente Medical Group, Pasadena, California
Corresponding author: Vivian Fonseca, vfonseca{at}tulane.edu
Abstract
OBJECTIVE —Observational studies assessing the association of combination therapy of metformin and sulfonylurea on all-cause and/or
cardiovascular mortality in type 2 diabetes have shown conflicting results. We therefore evaluated the effects of combination
therapy of sulfonylureas and metformin on the risk of all-cause mortality and cardiovascular disease (CVD) among people with
type 2 diabetes.
RESEARCH DESIGN AND METHODS —A MEDLINE search (January 1966–July 2007) was conducted to identify observational studies that examined the association between
combination therapy of sulfonylureas and metformin on risk of CVD or all-cause mortality. From 299 relevant reports, 9 were
included in the meta-analysis. In these studies, combination therapy of metformin and sulfonylurea was assessed, the risk
of CVD and/or mortality was reported, and adjusted relative risk (RR) or equivalent (hazard ratio and odds ratio) and corresponding
variance or equivalent was reported.
RESULTS —The pooled RRs (95% CIs) of outcomes for individuals with type 2 diabetes prescribed combination therapy of sulfonylureas
and metformin were 1.19 (0.88–1.62) for all-cause mortality, 1.29 (0.73–2.27) for CVD mortality, and 1.43 (1.10–1.85) for
a composite end point of CVD hospitalizations or mortality (fatal or nonfatal events).
CONCLUSIONS —The combination therapy of metformin and sulfonylurea significantly increased the RR of the composite end point of cardiovascular
hospitalization or mortality (fatal and nonfatal events) irrespective of the reference group (diet therapy, metformin monotherapy,
or sulfonylurea monotherapy); however, there were no significant effects of this combination therapy on either CVD mortality
or all-cause mortality alone.
Footnotes
Published ahead of print at http://care.diabetesjournals.org on 5 May 2008.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work
is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
Received February 7, 2008.
Accepted April 29, 2008.
DIABETES CARE |
|---|---|
| Bibliografia: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| ISSN: | 0149-5992 1935-5548 |
| DOI: | 10.2337/dc08-0167 |